Evaluation of the analgesic efficacy of AZD1940, a novel cannabinoid agonist, on post-operative pain after lower third molar surgical removal

Scandinavian Journal of Pain

Volumn 4, Issue 1, 2013, Pages 17-22

  Kalliomäki, Jarkko ^a   Segerdahl, Märta ^a   Webster, Lynn ^b   Reimfelt, Annika ^a   Huizar, Karin ^a   Annas, Peter ^a   Karlsten, Rolf ^a   Quiding, Hans ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b Lifetree Clinical Research   (United States)

Author keywords

Cannabinoid; Clinical trial; Dental extraction; Dental pain; Post operative pain; Tooth extraction

Indexed keywords

AZD 1940; CANNABINOID 1 RECEPTOR AGONIST; NAPROXEN; PARACETAMOL; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ANALGESIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DENTAL SURGERY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HYPOTENSION; JAW MOVEMENT; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN PARAMETERS; POSITIONAL DIZZINESS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT OUTCOME; VISUAL ANALOG MOOD SCALE; VISUAL ANALOG SCALE;

EID: 84872386048     PISSN: 18778860     EISSN: 18778879     Source Type: Journal    
DOI: 10.1016/j.sjpain.2012.08.004     Document Type: Article

References (40)

1. Campbell F.A., Tramer M.R., Carroll D., Reynolds D.J.M., Moore R.A., McQuay H.J. Are cannabinoids an effective and safe treatment option in the management of pain?. A qualitative systematic review. Br Med J 2001, 323:1-6.
2. Martin-Sanchez E., Furukawa T.A., Taylor J., Martin J.L.R. Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med 2009, 10:1353-1368.
3. Abrams D.I., Jay C.A., Shade S.B., Vizoso H., Reda H., Press S., Kelly M.E., Rowbotham M.C., Petersen K.L. Cannabis in painful HIV-associated sensory neuropathy. Neurology 2007, 68:515-521.
4. Ellis R.J., Toperoff W., Vaida F., van den Brande, Gonzales G., Gouaux J., Bentley B., Hampton Atkinson J. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 2009, 34:672-680.
5. Karst M., Salim K., Burstein S., Konrad I., Hoy L., Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain. J Am Med Assoc 2003, 290:1757-1762.
6. Nurmikko T.J., Serpell M.G., Hoggart B., Toomey P.J., Morlion B.J., Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomized, double-blind, placebo-controlled clinical trial. Pain 2007, 133:210-220.
7. Rog D.J., Nurmikko T.J., Friede T., Young C.A. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005, 65:812-819.
8. Svendsen K.B., Jensen T.S., Bach F.W. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. Br Med J 2004, 329:253-260.
9. Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anaesth 2006, 53:769-775.
10. Holdcroft A., Maze M., Doré C., Tebbs S., Thompson S. A multicenter study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology 2006, 104:1040-1046.
11. Jain A.K., Ryan J.R., McMahon F.G., Smith G. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol 1981, 21(Suppl. 8-9):S320-S326.
12. Kalliomäki J., Philipp A., Baxendale J., Annas P., Karlsten R., Segerdahl M. Lack of effect of central nervous system-active doses of nabilone on capsaicin-induced pain and hyperalgesia. Clin Exp Pharmacol Physiol 2012, 39:336-342.
13. Kraft B., Frickey N.A., Kaufmann R.M., Reif M., Frey R., Gustorff B., Kress H.G. Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology 2008, 109:101-110.
14. Naef M., Curatolo M., Petersen-Felix S., Arendt-Nielsen L., Zbinden A., Brenneisen R. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 2003, 105:79-88.
15. Noyes R., Brunk S.F., Avery D.A.H., Canter A.C. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 1975, 18:84-89.
16. Rukwied R., Watkinson A., McGlone F., Dvorak M. Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 2003, 102:283-288.
17. Wallace M., Schulteis G., Atkinson J.H., Wolfson T., Lazzaretto D., Bentley H., Gouaux B., Abramson I. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology 2007, 107:785-796.
18. Pertwee R.G. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Clin Pathol 2009, 156:397-411.
19. Piomelli D. The endocannabinoid system; a drug discovery perspective. Curr Opin Investig Drugs 2005, 6:672-679.
20. Holdcroft A., Hargreaves K.M., Rice A.S.C., Pertwee R.G. Cannabinoids and pain modulation in animals and humans. Progress in pain research and management 2000, vol. 16. IASP Press, Seattle, p. 915-26.
21. Rice A.S.C., Farquhar-Smith W.P., Bridges D., Brooks J.W. Cannabinoids and pain. Progress in pain research and management 2003, vol. 24. IASP Press, Seattle, p. 437-68.
22. Ständer S., Schmelz M., Metze D., Luger T., Rukwied R. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 2005, 38:177-188.
23. Agarwal N., Pacher P., Tegeder I., Amaya F., Constantin C.E., Brenner G.J., Rubino T., Michalski C.W., Marsicano G., Monory K., Mackie K., Marian C., Batkai S., Parolaro D., Fischer M.J., Reeh P., Kunos G., Kress M., Lutz B., Woolf C.J., Kuner R. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 2007, 10:870-879.
24. Clapper J.R., Moreno-Sanz G., Russo R., Guijarro A., Vacondio F., Duranti A., Tontini A., Sanchini S., Sciolino N.R., Spradley J.M., Hohmann A.G., Calignano A., Mor M., Tarzia G., Piomelli D. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosci 2010, 13:1265-1270.
25. 2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci 2005, 102:3093-3098.
26. 2 receptor-mediated anti-nociception in models of acute and chronic pain. Mol Neurobiol 2007, 36:26-35.
27. Yu X.H., Cao C.Q., Martino G., Puma C., Morinville A., St-Onge S., Lessard E., Perkins M.N., Laird J.M.A. A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain. Pain 2010, 151:337-344.
28. Page D., Wei Z., Liu Z., Tremblay M., Desfosses H., Milburn C., Srivastava S., Yang H., Brown W., Walpole C., Tomaszewski M., St-Onge S., Lessard E., Payza K., Panetta R., Yu X.H., Groblewski T. 5-Sulfonamide benzimidazoles: a class of cannabinoid receptors agonists with potent in vivo antinociception activity. Lett Drug Des Discov 2010, 7:208-213.
29. Groblewski T., Yu X.H., Lessard E., St-Onge S., Yang H., Panetta R., Cao C.Q., Swedberg M., Cebers G., Nyberg S., Schou M., Halldin C., Gulyas B., Varnäs K., Walpole C., Payza K., Perkins M., Ducharme J. Pre-clinical pharmacological properties of novel peripherally acting CB1-CB2 agonists. 20th annual symposium on the cannabinoids 2010, 37.
30. Groblewski T., Karlsten R., Segerdahl M., Kalliomäki J., Jonzon B., Bielenstein M., Cebers G., Swedberg M., Annas A., Christoph G., Tellefors P., Ståhle L., Bouw R., Fagerholm U., Berg A., Butler S., O'Malley M., Anstrén G. Peripherally acting CB1-CB2 agonists for pain: do they still hold promise?. 20th annual symposium on the cannabinoids 2010, 38.
31. Cooper S.A., Beaver W.T. A model to evaluate mild analgesics in oral surgery outpatients. Clin Pharmacol Ther 1976, 20:241-250.
32. Folstein M.F., Luria R. Reliability, validity, and clinical application of the visual analogue mood scale. Psychol Med 1973, 3:479-486.
33. ICH (International Conference on Harmonization). Good clinical practice guideline. [accessed 23.06.12]. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1_Guideline.pdf.
34. Michael Hill C., Sindet-Pederson S., Seymour R.A., Hawkesford J.E., Coulthard P., Lamey P.J., Gerry Cowan C., Wickens M., Jeppsson L., Dean A.D., Svensson O. Analgesic efficacy of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain: comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studies. Clin Ther 2006, 28:1279-1295.
35. Gustafsson I., Nyström E., Quiding H. Effect of preoperative paracetamol on pain after oral surgery. Eur J Clin Pharmacol 1983, 24:63-65.
36. Ong K.S., Seymour R.A., Yeo J.F., Ho K.H., Lirk P. The efficacy of preoperative versus postoperative rofecoxib for preventing acute postoperative dental pain. Clin J Pain 2005, 21:536-542.
37. Gilron I., Max M.B., Lee G., Boother S.L., Sang C.N., Chappel A.S., Dionne R.A. Effects of the 2-amino-3-hydroxy-5-methyl-4-isoxazole-proprionic acid/kainate antagonist LY293558 on spontaneous and evoked postoperative pain. Clin Pharmacol Ther 2000, 68:320-327.
38. Wesnes K.A., Annas P., Edgar C.J., Deeprose C., Karlsten R., Philipp A., Kalliomäki J., Segerdahl M. Nabilone produces marked impairment to cognitive function and changes in subjective state in healthy volunteers. J Psychopharmacol 2010, 24:1659-1669.
39. Block R.I., Farinpour R., Schlechte J.A. Effects of chronic marijuana use on testosterone, luteinizing hormone, follicle stimulating hormone, prolactin and cortisol in men and women. Drug Alcohol Depend 1991, 28:121-128.
40. Murphy L.L., Munoz R.M., Adrian B.A., Villanua M.A. Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion. Neurobiol Dis 1998, 5:432-446.